University of Surrey

Test tubes in the lab Research in the ATI Dance Research

Osteoarthritis year 2016 in review: biomarkers (biochemical markers)

Mobasheri, Ali, Bay-Jensen, A-C, van Spil, WE, Larkin, J and Levesque, MC (2017) Osteoarthritis year 2016 in review: biomarkers (biochemical markers) Osteoarthritis and Cartilage, 25 (2). pp. 199-208.


Download (817kB) | Preview
Text (licence)
Available under License : See the attached licence file.

Download (33kB) | Preview
[img] Text
1-s2.0-S1063458416304848-main.pdf - Version of Record
Restricted to Repository staff only
Available under License : See the attached licence file.

Download (870kB)


Purpose: The aim of this “Year in Review” article is to summarize and discuss the implications of biochemical marker related articles published between the Osteoarthritis Research Society International (OARSI) 2015 Congress in Seattle and the OARSI 2016 Congress in Amsterdam. Methods: The PubMed/MEDLINE bibliographic database was searched using the combined keywords: ‘biomarker’ and ‘osteoarthritis’. The PubMed/MEDLINE literature search was conducted using the Advanced Search Builder function ( Results: Over two hundred new biomarker-related papers were published during the literature search period. Some papers identified new biomarkers whereas others explored the biological properties and clinical utility of existing markers. There were specific references to several adipocytokines including leptin and adiponectin. ADAM Metallopeptidase with Thrombospondin Type 1 motif 4 (ADAMTS-4) and aggrecan ARGS neo-epitope fragment (ARGS) in synovial fluid (SF) and plasma chemokine (CeC motif) ligand 3 (CCL3) were reported as potential new knee biomarkers. New and refined proteomic technologies and novel assays including a fluoro-microbead guiding chip (FMGC) for measuring C-telopeptide of type II collagen (CTX-II) in serum and urine and a novel magnetic nanoparticle-based technology (termed magnetic capture) for collecting and concentrating CTX-II, were described this past year. Conclusion: There has been steady progress in osteoarthritis (OA) biomarker research in 2016. Several novel biomarkers were identified and new technologies have been developed for measuring existing biomarkers. However, there has been no “quantum leap” this past year and identification of novel early OA biomarkers remains challenging. During the past year, OARSI published a set of recommendations for the use of soluble biomarkers in clinical trials, which is a major step forward in the clinical use of OA biomarkers and bodes well for future OA biomarker development.

Item Type: Article
Subjects : Veterinary Medicine
Divisions : Faculty of Health and Medical Sciences > School of Veterinary Medicine
Authors :
Bay-Jensen, A-C
van Spil, WE
Larkin, J
Levesque, MC
Date : 19 January 2017
DOI : 10.1016/j.joca.2016.12.016
Copyright Disclaimer : © 2017 The Authors. Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International. This is an open access article under the CC BY-NC-ND license (
Uncontrolled Keywords : Osteoarthritis; Cartilage; Synovium; Biomarker; Biochemical marker; Assay
Depositing User : Symplectic Elements
Date Deposited : 18 Jan 2017 12:23
Last Modified : 16 Jan 2019 17:11

Actions (login required)

View Item View Item


Downloads per month over past year

Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800